Stock listing
KRX:008930 Hanmi Science Co., Ltd (한미사이언스) 주가
Follow Hanmi Science Co., Ltd into a list and get an email when it puts out news.
Share price · KRX:008930
₩51,700 KRW -700 (-1.3%)
Close on Nov 20, 2026
- Day range
- ₩50,200 – ₩54,300 KRWNov 20, 2026
- Volume
- 167,897 sharesNov 20, 2026
- Market cap
- ₩3.50T KRWAt the close on Nov 20, 2026 · price × 67.75M shares outstanding
- 52-week range
- ₩25,600 – ₩63,800 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩19.24B KRWMedian day 240,734 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:008930 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩51,700 | -700 | -1.3% | ₩50,900 | ₩54,300 | ₩50,200 | 167,897 | |
| ₩52,400 | -2,000 | -3.7% | ₩53,300 | ₩54,800 | ₩51,400 | 116,255 | |
| ₩54,400 | +1,400 | +2.6% | ₩53,500 | ₩54,800 | ₩52,500 | 127,238 | |
| ₩53,000 | +1,400 | +2.7% | ₩51,700 | ₩54,100 | ₩51,500 | 152,467 | |
| ₩51,600 | -3,200 | -5.8% | ₩52,300 | ₩53,500 | ₩50,800 | 271,681 | |
| ₩54,800 | -1,000 | -1.8% | ₩53,200 | ₩54,800 | ₩50,700 | 337,947 | |
| ₩55,800 | -1,400 | -2.4% | ₩57,300 | ₩60,400 | ₩54,400 | 452,548 | |
| ₩57,200 | -100 | -0.2% | ₩56,900 | ₩59,600 | ₩56,600 | 197,489 | |
| ₩57,300 | +3,000 | +5.5% | ₩54,400 | ₩58,500 | ₩54,400 | 309,663 | |
| ₩54,300 | +1,700 | +3.2% | ₩49,300 | ₩55,500 | ₩48,600 | 467,727 | |
| ₩52,600 | +3,600 | +7.3% | ₩50,000 | ₩53,300 | ₩49,950 | 368,292 | |
| ₩49,000 | +4,550 | +10.2% | ₩44,450 | ₩49,200 | ₩44,200 | 312,326 | |
| ₩44,450 | +950 | +2.2% | ₩43,700 | ₩46,150 | ₩42,850 | 207,326 | |
| ₩43,500 | +400 | +0.9% | ₩42,050 | ₩44,850 | ₩42,050 | 164,635 | |
| ₩43,100 | +900 | +2.1% | ₩43,000 | ₩43,350 | ₩40,050 | 314,105 | |
| ₩42,200 | +750 | +1.8% | ₩42,100 | ₩42,650 | ₩40,200 | 249,230 | |
| ₩41,450 | +50 | +0.1% | ₩41,500 | ₩45,350 | ₩41,250 | 269,190 | |
| ₩41,400 | -850 | -2.0% | ₩42,050 | ₩42,750 | ₩41,300 | 113,040 | |
| ₩42,250 | +650 | +1.6% | ₩40,700 | ₩43,250 | ₩40,700 | 114,214 | |
| ₩41,600 | -1,300 | -3.0% | ₩42,400 | ₩42,450 | ₩40,350 | 179,588 | |
| ₩42,900 | -700 | -1.6% | ₩42,950 | ₩44,850 | ₩42,700 | 150,721 | |
| ₩43,600 | -450 | -1.0% | ₩44,450 | ₩45,800 | ₩43,150 | 156,643 | |
| ₩44,050 | -1,500 | -3.3% | ₩45,200 | ₩46,850 | ₩42,500 | 208,018 | |
| ₩45,550 | -2,150 | -4.5% | ₩45,000 | ₩46,650 | ₩40,250 | 465,339 | |
| ₩47,700 | +2,250 | +5.0% | ₩44,450 | ₩49,500 | ₩44,150 | 258,930 | |
| ₩45,450 | +1,300 | +2.9% | ₩42,800 | ₩45,850 | ₩41,800 | 360,655 | |
| ₩44,150 | -6,050 | -12.1% | ₩49,000 | ₩49,300 | ₩43,400 | 402,084 | |
| ₩50,200 | -1,400 | -2.7% | ₩49,650 | ₩52,700 | ₩49,450 | 231,297 | |
| ₩51,600 | -3,300 | -6.0% | ₩52,100 | ₩53,800 | ₩49,400 | 379,438 | |
| ₩54,900 | -3,200 | -5.5% | ₩63,200 | ₩63,800 | ₩51,700 | 1,181,941 | |
| ₩58,100 | +500 | +0.9% | ₩57,800 | ₩58,800 | ₩56,400 | 702,637 | |
| ₩57,600 | +2,300 | +4.2% | ₩55,000 | ₩57,700 | ₩54,200 | 189,368 | |
| ₩55,300 | +2,600 | +4.9% | ₩52,600 | ₩55,700 | ₩51,000 | 162,367 | |
| ₩52,700 | -100 | -0.2% | ₩52,500 | ₩54,400 | ₩51,800 | 120,931 | |
| ₩52,800 | +600 | +1.1% | ₩52,500 | ₩53,700 | ₩51,100 | 126,865 | |
| ₩52,200 | -200 | -0.4% | ₩52,100 | ₩53,000 | ₩50,000 | 80,128 | |
| ₩52,400 | +300 | +0.6% | ₩52,500 | ₩53,500 | ₩51,300 | 103,889 | |
| ₩52,100 | +1,400 | +2.8% | ₩51,000 | ₩53,400 | ₩51,000 | 126,640 | |
| ₩50,700 | -100 | -0.2% | ₩50,900 | ₩51,200 | ₩49,950 | 83,261 | |
| ₩50,800 | +2,300 | +4.7% | ₩48,550 | ₩51,300 | ₩48,500 | 105,247 | |
| ₩48,500 | -2,400 | -4.7% | ₩50,900 | ₩51,300 | ₩48,300 | 576,323 | |
| ₩50,900 | -200 | -0.4% | ₩51,500 | ₩52,700 | ₩50,600 | 134,288 | |
| ₩51,100 | -500 | -1.0% | ₩51,300 | ₩52,000 | ₩49,400 | 155,024 | |
| ₩51,600 | +1,900 | +3.8% | ₩49,250 | ₩52,900 | ₩49,250 | 213,772 | |
| ₩49,700 | -600 | -1.2% | ₩49,100 | ₩50,600 | ₩47,950 | 250,377 | |
| ₩50,300 | -4,800 | -8.7% | ₩52,400 | ₩55,300 | ₩50,000 | 285,080 | |
| ₩55,100 | -900 | -1.6% | ₩55,000 | ₩56,300 | ₩51,400 | 497,443 | |
| ₩56,000 | -1,700 | -2.9% | ₩57,200 | ₩57,900 | ₩55,400 | 270,110 | |
| ₩57,700 | +3,500 | +6.5% | ₩54,400 | ₩61,000 | ₩53,300 | 818,252 | |
| ₩54,200 | +1,400 | +2.7% | ₩52,500 | ₩54,600 | ₩49,950 | 423,833 | |
| ₩52,800 | +1,300 | +2.5% | ₩51,900 | ₩54,400 | ₩51,450 | 320,035 | |
| ₩51,500 | +3,700 | +7.7% | ₩48,450 | ₩54,000 | ₩47,700 | 780,062 | |
| ₩47,800 | +2,000 | +4.4% | ₩44,700 | ₩48,750 | ₩44,600 | 413,719 | |
| ₩45,800 | +1,000 | +2.2% | ₩44,800 | ₩46,050 | ₩44,600 | 188,373 | |
| ₩44,800 | +300 | +0.7% | ₩43,500 | ₩45,100 | ₩42,900 | 196,400 | |
| ₩44,500 | +2,400 | +5.7% | ₩42,250 | ₩44,650 | ₩41,900 | 232,237 | |
| ₩42,100 | -2,300 | -5.2% | ₩43,300 | ₩45,150 | ₩41,800 | 441,518 | |
| ₩44,400 | -1,900 | -4.1% | ₩46,500 | ₩47,450 | ₩44,300 | 703,278 | |
| ₩46,300 | -10,200 | -18.1% | ₩52,500 | ₩52,500 | ₩45,050 | 1,455,867 | |
| ₩56,500 | +11,550 | +25.7% | ₩45,550 | ₩57,500 | ₩45,400 | 4,107,170 | |
| ₩44,950 | +700 | +1.6% | ₩43,350 | ₩45,600 | ₩43,000 | 175,368 | |
| ₩44,250 | -900 | -2.0% | ₩45,700 | ₩45,900 | ₩43,500 | 161,063 |
Splits
8 splits since 2009 · KRX:008930 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 51-for-50 | Split | |
| 51-for-50 | Split | |
| 21-for-20 | Split | |
| 21-for-20 | Split | |
| 5-for-1 | Split | |
| 21-for-20 | Split | |
| 1-for-4 | Consolidation | |
| 21-for-20 | Split |
- Ticker
- KRX:008930
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news release · Jan 28, 2026
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Latest news
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Jan 27, 2026
Closed ₩40,600 (+1.9%) on Jan 28, 2026
Hanmi Science Co., Ltd on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 1 in the last 12 months · 2 in all · newest Jan 28, 2026 · oldest 2025
Valuation
P/E 23.2× against a median of 18.5×: 7th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩3.40T KRW
- P/E
- 23.2×
- EV/sales
- 2.5×
- EV/EBITDA
- 57.2×
- Price/book
- 3.3×
- Gross margin
- 61.8%
- Operating margin
- 3.6%
- Net margin
- 10.8%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Hanmi Science Co., Ltd · KRX:008930 | US$2.60B | US$2.53B | 23.2× | 2.5× | 57.2× | 3.3× | 10.8% | 0.0× | n/a |
| China Medical System Holdings Ltd. · HKEX:867 | US$2.87B | US$2.13B | 12.8× | 1.7× | 7.7× | 1.1× | 18.1% | 0.1× | n/a |
| Joincare Pharmaceutical Group Industry Co., Ltd. Class A · SSE:600380 | US$2.80B | US$1.16B | 16.5× | 0.6× | n/a | 1.3× | 8.4% | 0.1× | n/a |
| Livzon Pharmaceutical Group, Inc. Class A · SZSE:000513 | US$2.72B | US$1.65B | 11.7× | 1.1× | n/a | 1.4× | 15.2% | 0.0× | n/a |
| Bavarian Nordic A/S · OMXCOP:BAVA | US$2.70B | US$2.38B | 20.5× | 2.6× | 8.6× | 1.4× | 14.2% | 0.0× | n/a |
| Betta Pharmaceuticals Co., Ltd. Class A · SZSE:300558 | US$2.64B | US$2.72B | 66.1× | 4.8× | n/a | 2.7× | 7.0% | 0.2× | n/a |
| Hybio Pharmaceutical Co., Ltd. Class A · SZSE:300199 | US$2.60B | US$2.71B | 43.1× | 11.8× | n/a | 16.1× | 26.3% | 0.9× | n/a |
| Hypera S.A. · BMFBOVESPA:HYPE3 | US$2.58B | US$3.55B | 8.5× | 2.3× | 7.4× | 1.0× | 20.1% | 0.5× | n/a |
| Kangmei Pharmaceutical Co., Ltd Class A · SSE:600518 | US$2.57B | US$2.37B | 189× | 3.3× | n/a | 2.3× | 1.9% | 0.0× | n/a |
| Granules India Limited · NSE:GRANULES | US$2.42B | US$2.32B | 31.4× | 3.6× | 16.1× | 3.4× | 12.1% | 0.2× | n/a |
| Prestige Consumer Healthcare Inc. · NYSE:PBH | US$2.35B | US$4.39B | 15.2× | 3.8× | 13.4× | 1.2× | 13.3% | 1.1× | 0.34 |
| Median of the others | US$2.62B | US$2.37B | 18.5× | 2.9× | 8.6× | 1.4× | 13.8% | 0.1× | 0.34 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | Apr 23, 2026 · Before open | +0.4% |
| Q3 2025 | Oct 29, 2025 · Before open | −3.0% |
| Q2 2025 | Jul 28, 2025 · Before open | −7.5% |
| Q1 2025 | Apr 25, 2025 · Before open | +0.3% |
| Q4 2024 | Feb 6, 2025 · Before open | +1.1% |
| Q3 2024 | Oct 31, 2024 · After close | −24.1% |
| Q2 2024 | Jul 30, 2024 · After close | −3.1% |
| Q1 2024 | May 3, 2024 · After close | +2.2% |
| Q4 2023 | Feb 2, 2024 · After close | −3.1% |
| Q3 2023 | Nov 1, 2023 · After close | +1.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Jul 28, 2023 · After close | −1.7% |
| Q1 2023 | Apr 26, 2023 · After close | −1.9% |
| Q4 2022 | Feb 8, 2023 · After close | +2.5% |
| Q3 2022 | Nov 1, 2022 · After close | +1.7% |
| Q2 2022 | Jul 26, 2022 · Before open | −0.3% |
| Q1 2022 | Apr 27, 2022 · Before open | +3.4% |
| Q3 2021 | Nov 4, 2021 | +0.3% |
| Quarter to Jun 30, 2021 | Jul 29, 2021 | −2.6% |
| Quarter to Mar 31, 2021 | Apr 27, 2021 | −2.2% |
| Quarter to Dec 31, 2020 | Feb 4, 2021 | −2.9% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.36T | 1.28T | 1.25T | 1.05T | 950.2B | 857.4B | 816.6B | 708.0B | 652.3B | 665.3B |
| Cost of revenue | 1.04T | 1.01T | 982.8B | 884.0B | 817.4B | 736.7B | 708.3B | 615.6B | 562.2B | 581.7B |
| Gross profit | 315.5B | 272.6B | 265.1B | 162.1B | 132.8B | 120.7B | 108.3B | 92.4B | 652.3B | 665.3B |
| Selling, general and administrative | 138.6B | 127.2B | 106.4B | 70.8B | 52.7B | 47.5B | 44.9B | 39.2B | 598.4B | 615.5B |
| Operating income | 57.0B | 38.0B | 57.0B | 28.1B | 28.8B | 25.2B | 16.1B | 11.0B | 14.0B | 15.1B |
| Depreciation and amortization | 9.48B | 9.71B | 8.73B | 5.48B | 5.26B | 6.21B | 6.37B | 4.61B | 4.68B | 3.20B |
| EBITDA | 66.4B | 47.7B | 65.7B | 33.6B | 34.0B | 31.4B | 22.5B | 15.6B | 18.7B | 18.3B |
| Interest expense | 10.6B | 11.3B | 10.2B | 3.69B | 1.79B | 1.70B | 1.73B | 1.10B | 0 | 0 |
| Income before tax | 133.0B | 63.1B | 130.5B | 73.2B | 49.1B | 30.0B | 35.4B | 18.8B | 33.4B | 18.9B |
| Income tax | 6.18B | 7.37B | 4.69B | 798.3M | 2.58B | 11.0B | ||||
| Net income | 118.4B | 59.4B | 115.1B | 69.2B | 42.9B | 22.6B | 30.7B | 18.0B | 30.1B | 7.94B |
| Earnings per share, basic | 1,748.09 | 877.54 | 1,693.40 | 1,038.20 | 638.33 | 349.47 | 475.27 | 278.54 | 464.73 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 127.4B | 85.2B | 27.6B | 21.4B | 16.6B | 14.8B | 16.7B | 26.9B | 38.4B | 102.5B |
| Short-term investments | 783.6M | 4.02B | 6.93B | 92.8M | 38.5M | 177.7M | 364.0M | 5.49B | ||
| Receivables | 104.4B | 102.1B | 106.9B | 98.8B | 93.5B | 86.6B | 91.1B | 101.4B | 107.5B | 127.3B |
| Inventory | 122.5B | 108.7B | 104.9B | 112.2B | 106.0B | 110.2B | 100.9B | 102.8B | 107.7B | 95.7B |
| Current assets | 425.8B | 328.0B | 273.9B | 245.3B | 222.6B | 215.7B | 217.1B | 244.5B | 261.3B | 330.0B |
| Property, plant and equipment | 26.0B | 25.6B | 26.3B | 25.7B | 27.1B | 27.7B | ||||
| Total assets | 1.49T | 1.35T | 1.23T | 1.11T | 949.9B | 923.2B | 910.8B | 916.5B | 938.8B | 969.2B |
| Accounts payable | 116.7B | 111.8B | 59.8B | 77.6B | 104.6B | 123.9B | 130.9B | 153.6B | 176.9B | 197.4B |
| Current liabilities | 483.5B | 468.8B | 395.2B | 347.7B | 221.0B | 220.1B | 228.2B | 227.2B | 244.6B | 304.7B |
| Long-term debt | 350.0M | 10.2B | 5.82B | 5.00B | ||||||
| Total liabilities | 529.9B | 510.4B | 438.7B | 384.9B | 259.6B | 264.5B | 265.1B | 263.5B | 273.6B | 321.7B |
| Shareholders' equity | 961.9B | 840.9B | 787.5B | 724.7B | 690.3B | 658.7B | 645.7B | 653.1B | 665.2B | 645.3B |
| Shares outstanding | 67.7M | 67.7M | 68.0M | 66.7M | 67.3M | 64.7M | 64.7M | 64.7M | 64.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 47.7B | 83.0B | 35.2B | 9.45B | 13.7B | 13.8B | 13.0B | 2.70B | -33.7B | 76.5B |
| Capital spending | -20.9B | -11.6B | -8.68B | -8.34B | -1.82B | -958.4M | -1.25B | -769.6M | -2.21B | -6.03B |
| Free cash flow | 26.7B | 71.3B | 26.5B | 1.11B | 11.5B | 11.9B | 11.1B | 1.52B | -37.8B | 70.5B |
| Cash from investing | -2.15B | -6.78B | -32.5B | 3.89B | -23.0B | -23.7B | ||||
| Cash from financing | -11.0B | -9.01B | 9.06B | -18.2B | -6.11B | -44.9B | ||||
| Dividends paid | -13.5B | -20.3B | -13.3B | -13.2B | -12.9B | -12.7B | -12.4B | -12.2B | -12.2B | -27.6B |
| Share buybacks | -1.93B | -7.83B | -622.6M | -1.01B | -348.3M | -647.3M | -998.1M | -834.5M | -1.77B | |
| Change in cash | 42.2B | 57.6B | 6.16B | 4.83B | 1.74B | -1.90B | -10.1B | -11.5B | -64.2B | 8.15B |
Cap table
Built by 6ix from Hanmi Science Co., Ltd’s releases
- Common shares
- 67,751,141
- Fully diluted
- 67,751,141
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 67,751,141 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 67,751,141 |
Log in to ask 6ix AI your own questions about Hanmi Science Co., Ltd.